MaaT Pharma SA

MaaT Pharma is planning to first target the European market with MaaT013 for acute graft-versus-host disease with gastrointestinal involvement (GI-aGVHD) as it seeks to raise money to bring its microb

With the 18-month clinical hold lifted on its lead microbiome therapy, MaaT Pharma SA is confident about securing a commercial partner and following Ferring Pharmaceuticals and Seres Therapeutics

The promise of microbiome-based therapeutics to treat a variety of diseases is considerable but so too are the concerns of regulators about a new class of drugs, as France's MaaT Pharma SA has once

French biotech companies raised their fair share of funds in 2021 as the industry saw record levels of investments while R&D flourished amid the continuing COVID-19 pandemic, a new survey reveals. The